Insmed Features the Global Phase 3 PALM Clinical Development Program Evaluating Treprostinil Palmitil Inhalation Powder (TPIP) at CHEST 2026
—Insmed's Largest Parallel-Running Clinical Effort to Date With Four Pivotal Phase 3 Studies Advancing Across Four Progressive Pulmonary Diseases: PALM-PAH, PALM-ILD, PALM-PPF, and PALM-IPF— —One of the Broadest Active Global Clinical Programs in the Pulmonary Space, With the Potential to...